873581-24-9

Upstream product

• 684283-02-1 methyl 2-(benzyloxycarbonylamino)-2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 100945-15-1 N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester 

Downstream Products

• 1241377-40-1 methyl (2S)-{[(benzyloxy)carbonyl]amino}(4,4-difluorocyclohexyl)ethanoate 
• 394735-61-6 C₉H₁₅F₂NO₂ 
• 1241377-43-4 C₁₁H₁₇F₂NO₄ 
• 1241377-45-6 (S)-2-(4,4-difluorocyclohexyl)-2-(methoxycarbonylamino)acetic acid 
• 1359869-32-1 C₁₁H₁₇NO₅ 
• 1359869-33-2 Cap-197 
• 676596-50-2 C₁₄H₂₅NO₅ 
• 676596-50-2 C₁₄H₂₅NO₅ 
• 463349-85-1 methyl (2S)-[(tert-butoxycarbonyl)amino](4-hydroxycyclohexyl)ethanoate trans-isomer 
• 667898-96-6 methyl (2S)-[(tert-butoxycarbonyl)amino](4-hydroxycyclohexyl)ethanoate cis-isomer 
• 848498-04-4 (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-oxocyclohexyl)acetate 
• 1266233-13-9 (3S,7,8aR)-2-[(2S)-2-amino-2-(4,4-difluorocyclohexyl)acetyl]-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]-7-hydroxyoctahydropyrrolo[1,2-a]pyrazine-3-carboxamide 
• 1266229-86-0 benzyl {(1S)-1-(4,4-difluorocyclohexyl)-2-[(3S,7R,8aR)-3-[(4R)-3,4-dihydro-2H-chromen-4-yl-carbamoyl]-7-ethoxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-oxoethyl}carbamate 
• 1266233-10-6 benzyl {(1S)-1-(4,4-difluorocyclohexyl)-2-[(3S,7R,8aR)-3-[(4R)-3,4-dihydro-2H-chromen-4-ylcarbamoyl]-7-hydroxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-oxoethyl}carbamate 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection of following Fomula (I). Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

AZAINDOLE INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3', R4, R4', R5, R6, R6' and R9 are as described herein.

INHIBITORS OF IAP

The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X1, X2, X3, Y, A, R1, R2, R3, R4, R4', R5, R5'/

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.